Zynerba Pharmaceuticals Inc.

0.560000.00Vol 14.56K1Y Perf -83.38%
Dec 2nd, 2022 10:34 DELAYED
BID0.5514 ASK0.5690
Open0.5600 Previous Close0.5600
Pre-Market0.56 After-Market-
 - -%  - -
Target Price
7.00 
Analyst Rating
Moderate Buy 1.80
Potential %
1.13K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
1.93 
Earnings Rating
Strong Buy
Market Cap26.35M 
Earnings Date
21st Nov 2022
Alpha-0.03 Standard Deviation0.28
Beta1.93 

Today's Price Range

0.55340.5745

52W Range

0.50013.61

5 Year PE Ratio Range

-2.10-4.70

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-0.93%
1 Month
-22.73%
3 Months
-50.45%
6 Months
-42.78%
1 Year
-83.38%
3 Years
-90.99%
5 Years
-96.19%
10 Years
-

TickerPriceChg.Chg.%
ZYNE0.56000.00000.00
AAPL146.43-1.8850-1.27
GOOG100.03-1.2500-1.23
MSFT251.83-2.8600-1.12
XOM110.920.12000.11
WFC45.07-1.8050-3.85
JNJ177.25-1.4900-0.83
FB196.640.99000.51
GE85.410.15000.18
JPM134.00-2.2400-1.64
 
ProfitabilityValueIndustryS&P 500US Markets
-
-35 988.20
-35 843.30
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.21-0.204.76
Q02 2022-0.21-0.24-14.29
Q01 2022-0.22-0.214.55
Q04 2021-0.27-0.2218.52
Q03 2021-0.23-0.26-13.04
Q02 2021-0.20-0.25-25.00
Q01 2021-0.24-0.2016.67
Q04 2020-0.38-0.3313.16
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.209.09Positive
12/2022 FY-0.865.49Positive
3/2023 QR-0.218.70Positive
12/2023 FY-0.6815.00Positive
Next Report Date-
Estimated EPS Next Report-0.21
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume14.56K
Shares Outstanding47.06K
Shares Float41.68M
Trades Count85
Dollar Volume8.16K
Avg. Volume280.81K
Avg. Weekly Volume205.89K
Avg. Monthly Volume326.46K
Avg. Quarterly Volume310.09K

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) stock closed at 0.56 per share at the end of the most recent trading day (a 3.29% change compared to the prior day closing price) with a volume of 86.90K shares and market capitalization of 26.35M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 28 people. Zynerba Pharmaceuticals Inc. CEO is Armando Anido.

The one-year performance of Zynerba Pharmaceuticals Inc. stock is -83.38%, while year-to-date (YTD) performance is -80.73%. ZYNE stock has a five-year performance of -96.19%. Its 52-week range is between 0.5001 and 3.61, which gives ZYNE stock a 52-week price range ratio of 1.93%

Zynerba Pharmaceuticals Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 0.50, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -47.04%, a ROC of -54.78% and a ROE of -54.52%. The company’s profit margin is -%, its EBITDA margin is -35 843.30%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Zynerba Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. Zynerba Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Zynerba Pharmaceuticals Inc. is Moderate Buy (1.8), with a target price of $7, which is +1 130.66% compared to the current price. The earnings rating for Zynerba Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Zynerba Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Zynerba Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.66, ATR14 : 0.05, CCI20 : -67.19, Chaikin Money Flow : -0.10, MACD : -0.05, Money Flow Index : 25.16, ROC : -11.04, RSI : 40.32, STOCH (14,3) : 38.52, STOCH RSI : 0.78, UO : 50.42, Williams %R : -61.48), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Zynerba Pharmaceuticals Inc. in the last 12-months were: Armando Anido (Sold 11 899 shares of value $13 089 ), Brian Rosenberger (Sold 4 289 shares of value $4 718 ), Daniel L. Kisner (Sold 40 shares of value $40 ), James E. Fickenscher (Sold 6 013 shares of value $6 614 ), John P. Butler (Sold 53 shares of value $54 ), Kenneth I. Moch (Sold 40 shares of value $40 ), Pamela Stephenson (Sold 40 shares of value $40 ), Terri B. Sebree (Sold 8 281 shares of value $9 109 ), Warren D. Cooper (Sold 40 shares of value $40 ), William J. Federici (Sold 40 shares of value $40 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (60.00 %)
4 (80.00 %)
4 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (40.00 %)
1 (20.00 %)
1 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.80
Strong Buy
1.40
Strong Buy
1.40

Zynerba Pharmaceuticals Inc.

Zynerba Pharmaceuticals Inc together with its subsidiary is a pharmaceutical company which is focused on developing and commercializing proprietary next generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates are ZYN001 and ZYN002. The company has initiated a clinical trial for both the product candidates.

CEO: Armando Anido

Telephone: +1 484 581-7505

Address: 80 West Lancaster Avenue, Devon 19333, PA, US

Number of employees: 28

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

53%47%

Bearish Bullish

45%55%

TipRanks News for ZYNE

Wed, 10 Aug 2022 15:05 GMT Zynerba Pharmaceuticals (ZYNE) Gets a Hold from Needham

- TipRanks. All rights reserved.

News

Stocktwits